drugset
drugset / Trial / NCT01467375

Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetes

NCT01467375 ↗

Phase 3 Completed 89 enrolled Novo Nordisk A/S
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This trial is conducted in Oceania and North America. The aim of this trial is to assess the long term safety and efficacy of biphasic insulin aspart 30 in subjects with type 2 diabetes who have completed the BIAsp-1234 trial.

Timeline

Start
2001-01-08
Primary completion
2004-10-22
Completion
2004-10-22

Drugs

EvaluationDrugModalityDoseRoute
Subject biphasic insulin aspart Protein / enzyme biologic — Subcutaneous

Indications

type 2 diabetes mellitus